Allergy Therapeutics plc (AGY) is a Drug manufacturers specialty generic company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Allergy Therapeutics plc in 2026. The next earnings report is expected on September 24, 2026.
Next earnings date
24 Sep 2026
In 34 days
EPS estimate
-0.01
Revenue estimate
35.4M
Past earnings
No dividend history available.
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Allergy Therapeutics plc (AGY) is scheduled to report earnings on September 24, 2026.
Allergy Therapeutics plc (AGY) last reported earnings on March 31, 2026.
Allergy Therapeutics plc (AGY) is listed on London Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.